Teladoc Health, Inc. (NYSE: TDOC) recently received the rating of “Buy” after a consensus from analysts of thirty-one brokerages covering this stock.
Among the thirty-one analysts’ ratings, thirteen have given out a rating of “Hold” and a majority of fifteen brokerages have rated the company as “buy”. The 52-week target price as set by these brokerages stand at $229.77.
TDOC stocks traded at $196.34 this Friday. The company’ current market capitalization stands at $28.46 billion. It has a negative PE ratio of 153.39 along with a beta of 0.25 at the moment. The 12-monthly high to low ranges from $253.00 to $80.49. The 50SMA (50 Days Simple Moving Average) stands at $194.51 and its 200SMA stands at $203.95. The debt-to-equity of this company is 0.73. The current and quick ratio is 11.36.
Teladoc Health, Inc. (NYSE: TDOC) Stock Analysis
The quarterly earnings report for the previous quarter was released on the 28th of October. The earnings stood at $0.43 EPS as opposed to the general consensus of $0.33 proposed by several equities’ analysts. The company’s return on equity stands at -9.54% along with the net margin of 13.22%. The estimated income for the firm was marked at $281.54 million but it made $288.81 million for the quarter. Expert analysts further expect that the company will post its FY2020 earnings of -1.4 per share.
NYSE: TDOC has recently been the subject of a lot of reports by research analysts. Some such as Piper Sandler, ValuEngine, Oppenheimer, Goldman Sachs Group, Berenberg Bank, and so on have posted reports on this company over the last few months.
Several hedge funds and institutional investors have also been involved in buying and selling of TDOC shares recently. Among some of the notable ones, SVP Andrew Turitz, Adam C. Vandervoort and so on changed their stock holdings of this company.
